Jian Xu,Lixin Zhang,Guo Wu et al.
Jian Xu et al.
Erratum: De-escalating local therapies without compromising outcomes: lessons from the COLLISION trial [0.03%]
校正：去escalate局部治疗而不影响结果：COLLISION试验的启示
Editorial Office
Editorial Office
[This corrects the article DOI: 10.21037/hbsn-2025-238.]. © AME Publishing Company.
Published Erratum
Hepatobiliary surgery and nutrition. 2026 Apr 1;15(2):64. DOI:10.21037/hbsn-2026-0145 2026
Dapagliflozin for metabolic dysfunction-associated steatohepatitis with fibrosis: a promising therapeutic agent in biopsy-diagnosed patients [0.03%]
达格列净治疗伴纤维化的代谢紊乱相关非酒精性脂肪肝病：一项活检确诊患者的 promise 治疗药物研究
Soo Kyoung Kim,Hyeong Seok An,Gu Seob Roh
Soo Kyoung Kim
Phenotypic personalized tacrolimus dosing: a step toward precision immunosuppression in liver transplantation [0.03%]
肝移植中的个性化他克莫司给药：迈向精准免疫抑制的第一步
Christopher Hartley,Yan Shu,Wikrom Karnsakul
Christopher Hartley
Robotic-assisted hepatopancreatoduodenectomy for intraductal papillary neoplasm of the bile duct: future approach for minimally invasive biliary surgery [0.03%]
胆管乳头状黏液性肿瘤的机器人辅助肝胰十二指肠切除术：未来微创胆道手术的新途径
Zhujing Lan,Tiansheng Lan,Weitao Chen et al.
Zhujing Lan et al.
Association of a novel glycemic control index, time in range, with infectious complications after pancreatectomy [0.03%]
新颖的血糖控制指标：血糖值在目标范围时间与胰腺切除术后感染并发症的关系
Yuichiro Kohara,Satoshi Yasuda,Minako Nagai et al.
Yuichiro Kohara et al.
Background: Time in range (TIR) reflects glycemic variability and is a widely used index for glycemic control in patients with diabetes; however, it is unclear whether it is associated with infectious complications after ...
Balancing safety and outcomes in minimally invasive liver resection: insights from the PRESSURE trial [0.03%]
微创肝切除术中安全性和效果的平衡：PRESSURE试验带来的启示
Nicholas Ken Jin Ang,Kah Ming Eddy Saw,Ye Xin Koh et al.
Nicholas Ken Jin Ang et al.
Revisiting the two-stage hepatectomy and hepatic arterial infusion chemotherapy for colorectal liver metastases: insights and long-term outcomes from a large cohort [0.03%]
再访两阶段肝切除和肝动脉灌注化疗治疗结直肠癌肝转移的见解及长期结果：来自大样本队列的启示
Tom Vandaele,Mathieu D&#x;Hondt
Tom Vandaele
Engineering the tumor microenvironment via 3D multicellular bioprinting for personalized immunotherapy assessment and resistance deciphering [0.03%]
基于个性化免疫治疗评估和耐药性解析的三维多细胞生物打印技术构建肿瘤微环境
Feihu Xie,Meiheban Bazhabayi,Yun Zheng
Feihu Xie